Teleconsultation has gained significant traction due to advancements in information and communication technologies. While much attention has been given to physician-to-patient teleconsultation, the factors influencing physician-to-physician teleconsultation remain underexplored.
This scoping review aims to map and synthesise the existing evidence on the factors influencing physician-to-physician teleconsultation.
We included publications of all methodological designs that specifically addressed factors affecting physician-to-physician teleconsultation. Studies focusing primarily on physician-to-patient teleconsultation without sufficient detail on physician-to-physician components were excluded. The search was limited to articles published in English and Persian between 2014 and 2024.
Eight electronic databases (PubMed, Scopus, Web of Science, etc) were searched from January 2014 to June 2024.
Data extraction was performed by two independent reviewers using a standardised form. Extracted data included study characteristics, key factors influencing teleconsultation and main findings.
From 12 included studies, five key influencing components were identified: ‘patient-related factors’, ‘medical team competencies’, ‘infrastructure and technology’, ‘timing factors’ and ‘planning and programme evaluation’. Among these, infrastructure and technology were the most frequently reported factors across the studies, while patient-related factors were less commonly addressed.
This review identifies a comprehensive set of factors that influence physician-to-physician teleconsultation. The findings provide a foundation for developing effective teleconsultation programmes and highlight the need for more research in diverse healthcare settings.
by Ramtin Naderian, Sajjad Ahmad, Mojgan Rahmanian, Shahrzad Aghaamoo, Aryan Rahbar, Omid Pajand, Akram Alizadeh, Shahin Nazarian, Samira Sanami, Majid Eslami
Chandipura virus (CHPV) is endemic in India, with frequent outbreaks reported. No approved medicines or vaccines exist for CHPV. We aimed to develop a multi-epitope vaccine for CHPV using immunoinformatics approaches. In this study, a multi-epitope vaccine construct was developed by combining 11 CTL epitopes, 2 HTL epitopes, and 1 linear B-cell epitope from glycoprotein (G) with 1 EAAAK linker, 10 AAY linkers, 2 GPGPG linkers, 1 KK linker, and adjuvant (RS-09 peptide). We predicted and optimized the vaccine’s protein structure. Furthermore, the vaccine 3D structure was docked with Toll-like receptor 4 (TLR4) using the Cluspro 2.0 server, and the docked complex was analyzed using molecular dynamics (MD) simulation by the assisted model building with energy refinement (AMBER) v.20 package. The vaccine’s immune simulation profile was determined, and the vaccine sequence was reverse translated and in silico cloned into the pET28a (+). The vaccine’s population coverage was 99.79% across the worldwide. The vaccine was soluble, non-allergenic and non-toxic, with high levels of antigenicity. The quality of the vaccine’s 3D structure improved following refining, and the number of residues in the most favoured regions of the Ramachandran plot increased by 94.2%. The molecular docking, with a docking score of −1157 kcal/mol, and MD simulation results revealed a robust interaction and remarkable stability between the vaccine and TLR4. The immune response simulation indicated a decrease in antigen levels and an increase in interferon‐gamma (IFN‐γ) and interleukin-2 (IL-2) concentrations after each injection. In silico results indicate that this vaccine possesses significant promise against CHPV; however, laboratory and animal studies are necessary to validate our findings.